On May 21, 2019 Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, reported it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019 (Press release, Genprex, MAY 21, 2019, View Source [SID1234536505]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Taking place on the first day of ASCO (Free ASCO Whitepaper), the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. Genprex will be among the 30+ presentations by listed and private biotechnology companies at the event.
Several networking opportunities are still available to investors or delegates of other companies that may wish to meet the Genprex team one-on-one. Those interested in setting a meeting are asked to contact the company at [email protected].
Genprex will present at the Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum as follows:
Date: Friday, May 31, 2019
Time: 11:10 a.m. CT
Venue: Waldorf Astoria Chicago
Room: Sinclair Ballroom
Genprex’s President and Chief Operating Officer, Julien Pham, MD, MPH, will lead the company’s presentation and will be available for one-on-one meetings.